Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02456532 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy of Chronic Hypnotic Use 2

A Phase 4 study, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 4
Development phase
41
Enrollment target

NCT02456532 is a Phase 4 study that has completed, run by Henry Ford Health System. The registered enrollment target is 41 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02456532, a Phase 4 study, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 4
Development phase
41 participants
Enrollment target

Study Summary

This proposal will assess risks for transition from therapeutic hypnotic use to abuse in people with insomnia. The investigators will study a hypothesized at-risk sub-population, insomniacs with hyperarousal, and compare two hypnotics, a drug with mood effects, eszopiclone, versus one without mood effects, zolpidem.

Interventions

  • DRUG placebo
  • DRUG Eszopiclone
  • DRUG Zolpidem CR

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2015-08-05
Est. Completion 2022-02-22
Phase Phase 4

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT02456532

The ClinicalTrials.gov registry entry for NCT02456532 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT02456532 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02456532 about?

NCT02456532 is a clinical study titled "Safety and Efficacy of Chronic Hypnotic Use 2". This proposal will assess risks for transition from therapeutic hypnotic use to abuse in people with insomnia. The investigators will study a hypothesized at-risk sub-population, insomniacs with hyperarousal, and compare two hypnotics, a drug with mood effects, eszopiclone, versus one without mood e...

What is the current status of trial NCT02456532?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2015-08-05. Estimated completion is 2022-02-22.

What interventions are being tested in trial NCT02456532?

The interventions under investigation include: placebo (DRUG), Eszopiclone (DRUG), Zolpidem CR (DRUG).

Who is sponsoring clinical trial NCT02456532?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.